Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation: A Randomized Controlled Study in African American Women Living in Low-income Urban Environments
The purpose of the study is to test whether nutritional supplementation during pregnancy is associated with 1) improved maternal health during pregnancy; 2) improved infant birth and neurodevelopmental outcomes, and 3) whether the association between nutritional supplementation during pregnancy and infant outcomes is partially mediated by reductions in maternal perceived stress and stress reactivity during pregnancy.
One hundred sixty-two pregnant women will be randomly assigned to receive 450 mg/daily of DHA or placebo beginning at 9-12 weeks of gestation through the end of pregnancy. Perceived stress, stressful life events, anxiety, and depression, inflammatory markers, DHA levels and response to a laboratory stressor will be assessed at baseline and at 24, 30, and 36 weeks of pregnancy. Neonatal outcomes (e.g., gestational age, birth weight, delivery complications) will be collected from medical records, and infant neurodevelopmental outcomes and stress reactivity will be assessed at 1, 4 and 9 months of age. Coded data will be analyzed by the Investigators at University of Chicago and University of Pittsburgh
18 Years to 34 Years
Accepting Healthy Volunteers?
Accepts Healthy Volunteers
- Age between 18 and 34
- Household recipient of public assistance (e.g. Medicaid insurance) due to low income
- Low levels of DHA consumption as defined as less than two fish servings per week
- Reports of known medial complications
- Regular use of steroid medications, alcohol, cigarettes, or illegal substances (by maternal report)
- Use of blood thinners or anti-coagulants
- Use of psychotropic medications
- Allergy to iodine and/or soy